Recommandé
Contenu connexe
Plus de Oregon Health & Science University
Plus de Oregon Health & Science University (20)
Dernier
Dernier (20)
Doernbecher clinical trials april 2011
- 1. Pediatric Echocardiogram Lab Expansion A Summary for Norman and Susan Hand Page Doernbecher Pediatric Oncology Phase I & II trials Treatment Group ID Number Phase Study Name Site Investigator and coordinator BRAIN TUMORS Ependymoma PETEY 774- II A randomized, Phase II study of single agent Kellie Nazemi, MD 205 Erlotinib versus oral etoposide in patients with 503-494-0829 recurrent or refractory pediatric Ependymoma (OSI ) Rae Acosta RN, CPON 503-418-4467 Recurrent Low-Grade RAD001 II A phase II study of RAD001 (Everolimus) for Kellie Nazemi, MD Gliomas children with chemotherapy and/or Radiation 503-494-0829 (POETIC) refractory progressive or recurrent low grade gliomas Rae Acosta RN, CPON 503-418-4467 High Grade Gliomas ACNS0621 II Cilengitide (EMD 12194) in recurrent or Kellie Nazemi, MD progressive and refractory childhood high grade 503-494-0829 (COG) Glioma Rae Acosta RN, CPON 503-418-4467 Childhood ACNS0821 II Temozolomide with Irinotecan versus Kellie Nazemi, MD Medulloblastoma / CNS Temozolomide plus Bevacizumab for refractory/ 503-494-0829 PNET (COG) Recurrent Medulloblastoma/CNS PNET of child- hood, a COG Phase II randomized trial Rae Acosta RN, CPON 503-418-4467 Newly diagnosed High ACNS0822 I/II A randomized Phase I/II study of Vorinostat Kellie Nazemi, MD Grade Gliomas And local irradiation OR Temozolomide and 503-494-0829 (COG) Local irradiation OR Bevacizumab and local Irradiation followed by maintenance Bevacizu- Rae Acosta RN, CPON mab and Temozolomide in children with newly 503-418-4467 Diagnosed High grade gliomas. Newly diagnosed diffuse ACNS0927 I/II A phase I/II study of Suberoylanilide Hydrox- Kellie Nazemi, MD Intrinsic Pontine Glioma amic 503-494-0829 (DIPG) (COG) Acid (SAHA,Vorinostat) and local irradiation, Followed by maintenance SAHA in children with Rae Acosta RN, CPON Newly diagnosed DIPG 503-418-4467
- 2. Pediatric Echocardiogram Lab Expansion A Summary for Norman and Susan Hand Page 2 Doernbecher Pediatric Oncology Phase I & II trials Treatment Group ID Number Phase Study Name Site Investigator and coordinator Solid Tumors Solid Tumors ADVL0813 I A Phase I study of IMC-A12 (anti-insulin-like Suman Malempati, MD Growth factor-1 Receptor Monoclonal antibody) (COG) in combination with CCI-779 (temsirolimus) in Rae Acosta RN, CPON Pediatric patients with recurrent or refractory 503-418-4467 solid tumors Solid Tumors ADVL0815 I A phase I study of Pazopanib as a single agent for Suman Malempati, MD children with refractory solid tumors (COG) Rae Acosta RN, CPON 503-418-4467 Solid Tumors or ADVL0816 I A phase I study of Obatoclax (Pan Anit- Suman Malempati, MD Leukemia Apoptotic BCL-2 family small molecule inhibi- (COG) tor), in combination with Vincristine/ Rae Acosta RN, CPON Doxorubicin/ Dexrazoxane, in children with 503-418-4467 Relapsed/Refractory solid tumors or Leukemia Solid Tumors ADVL0821 II A phase II study of IMC-A12 in children with Suman Malempati, MD Relapsed or refractory solid tumors (COG) Rae Acosta RN, CPON 503-418-4467 Solid Tumors and ALCL ADVL0912 I/II PF-02341066 for ALK and C-Met for patients Suman Malempati, MD with relapsed or refractory solid tumors and (COG) ALCL Rae Acosta RN, CPON 503-418-4467 Recurrent or Refractory ADVL1013 I A Phase I study of MK-2206, an AKT inhibitor Suman Malempati, MD Solid Tumors or In Pediatric patients with recurrent or refractory Leukemia (COG) Solid tumors or Leukemia Rae Acosta RN, CPON 503-418-4467
- 3. Pediatric Echocardiogram Lab Expansion A Summary for Norman and Susan Hand Page 3 Doernbecher Pediatric Oncology Phase I & II trials Treatment Group ID Number Phase Study Name Site Investigator and coordinator Solid Tumors Solid Tumors ADVL1011 I A phase I study of JAK Inhibition in children Suman Malempati, MD With Relapsed or Refractory Solid Tumors, (COG) Rae Acosta RN, CPON 503-418-4467 Solid Tumors ADVL0918 I A phase I study of of Temsirolimus in combina- Suman Malempati, MD tion with Irinotecan and Temozolomide in (COG) children , adolescents and young adults with Rae Acosta RN, CPON relapsed or refractory solid tumors 503-418-4467 Solid Tumors AMG954- I Suman Malempati, MD 20050252 Panitumumab in children with solid tumors Rae Acosta RN, CPON (Amgen) 503-418-4467 Solid Tumors ADVL0413 I A phase I study of the Raf Kinase and Receptor Suman Malempati, MD Tyrosine Kinase Inhibitor Sorafenib in children (COG) With refractory solid tumors or refractory Rae Acosta RN, CPON Leukemia's 503-418-4467 Solid Tumors ADVL0612 I A phase I study of Sunitinib and oral multi- Suman Malempati, MD targeted tyrosine kinase inhibitor, in children with (COG) refractory solid tumors Rae Acosta RN, CPON 503-418-4467
- 4. Pediatric Echocardiogram Lab Expansion A Summary for Norman and Susan Hand Page 4 Doernbecher Pediatric Oncology Phase I & II trials Treatment Group ID Number Phase Study Name Site Investigator and coordinator LEUKEMIA STUDIES Philadelphia AALL0622 II Intensified Tyrosine Kinase Inhibitor Therapy Bill Chang, MD Chromosome + ALL (Dasatinib) in Philadelphia Chromosome + ALL (COG) Rae Acosta RN, CPON 503-418-4467 Relapsed KITE 2046 I/II Bendamustine (Treanda) in relapsed pediatric Bill Chang, MD Acute Leukemia ALL (Cephalon, Inc) Rae Acosta RN, CPON 503-418-4467 Pediatric AML E7373-G000- Pilot Pre-Induction Decitabine Priming for Pediatric Linda Stork, MD 202 AML subjects Rae Acosta RN, CPON (Eisai, Inc) 503-418-4467 Leukemia's and ADVL1011 I A phase I study of JAK Inhibition in children Suman Malempati, MD Myeloproliferative With Relapsed or Refractory Solid Tumors, Neoplasm's, (COG) Rae Acosta RN, CPON Solid Tumors 503-418-4467 Ph+ Leukemia CA180226 II Dasatinib in Children and Adolescents with Ph+ Linda Stork, MD Leukemia with resistance or Intolerance to (BMS) Imatinib Rae Acosta RN, CPON 503-418-4467 Recurrent or Refractory ADVL1013 I A Phase I study of MK-2206, an AKT inhibitor Suman Malempati, MD Solid Tumors or In Pediatric patients with recurrent or refractory Leukemia (COG) Solid tumors or Leukemia Rae Acosta RN, CPON 503-418-4467
- 5. Pediatric Echocardiogram Lab Expansion A Summary for Norman and Susan Hand Page 5 Doernbecher Pediatric Oncology Phase I & II trials Treatment Group ID Number Phase Study Name Site Investigator and coordinator LEUKEMIA STUDIES Solid Tumors or ADVL0816 I A phase I study of Obatoclax (Pan Anit- Suman Malempati, MD Leukemia Apoptotic BCL-2 family small molecule inhibi- (COG) tor), in combination with Vincristine/ Rae Acosta RN, CPON Doxorubicin/ Dexrazoxane, in children with 503-418-4467 Relapsed/Refractory solid tumors or Leukemia Solid Tumors or ADVL0413 I A phase I study of the Raf Kinase and Receptor Suman Malempati, MD Refractory Leukemia Tyrosine Kinase Inhibitor Sorafenib in children (COG) With refractory solid tumors or refractory Rae Acosta RN, CPON (AML and FLT3-ITD Leukemia's 503-418-4467 mutation) CD-22 + Leukemia ADVL04P2 I/II A phase I/II pilot study of Chemoimmunotherapy Suman Malempati, MD With Epratuzumab for children with Relapsed (COG) CD-22 + ALL Rae Acosta RN, CPON 503-418-4467 Rhabdomyosarcoma Studies High Risk ARST08P1 Pilot A pilot study to evaluate novel agents Suman Malempati, MD Rhabdomyocarcoma (Temozolomide and Cixutumumab) in (COG) combination with intensive multi-agent interval Rae Acosta RN, CPON Compressed therapy for patients with high risk 503-418-4467 Rhabdomyosarcoma Rhabdomyosarcoma ARST0921 II A randomized Phase II trial of Bevacizumab Suman Malempati, MD (Avastin) and Temsirolimus (Torisol) in (COG) Combination with IV Vinorelbine and Rae Acosta RN, CPON Cyclophosphamide in subjects with recurrent or 503-418-4467 Refractory Rhabdomyosarcoma
- 6. Pediatric Echocardiogram Lab Expansion A Summary for Norman and Susan Hand Page 6 Doernbecher Pediatric Oncology Phase I & II trials Treatment Group ID Number Phase Study Name Site Investigator and coordinator Bonemarrow and stem cell transplant protocols Severe aplastic anemia BMT CTN I/II Fludarabine-based conditioning for allogeneic Gabrielle Meyers, MD 0301 marrow transplantation from HLA compatible 503-494-1551 unrelated donors in severe aplastic anemia (BMT CTN) Allison Moore RN 503-418-5341 Hodgkins disease and BUMELTT II A phase II study to evaluate the safety and Richard Maziarz, MD non-hodgkins lymphoma efficacy of IV busulfan, melphalan, and thiotepa 503-494-1551 (OHSU) (BuMelTT) regimen followed by autologous PBSC infusion for patients with hodgkins disease Allison Moore RN and non-hodgkins lymphoma 503-418-5341l Hematologic BU/FLU/TBI I/II A Phase I/Il non-myeloablative allogenic Richard Maziarz, MD malignancies Hematopoietic stem cell transplant for the 503-494-1551 (OHSU) Treatment of patients with hematologic malig- nancies using busulfan, fludarbine and total body Allison Moore RN irradiation 503-418-5341 Hematologic T2008-005 I Phase I feasibility study of clofarabine and low Eneida Nemecek, MD malignancies dose total body irradiation (TBI) as a non- 503-494-0829 (TACL) Myeloblative preperative regimen for stem cell Multicenter transplant (SCT) for hematologic malignancies Allison Moore RN 503-418-5341 Ph+ Leukemia FHCRC 2223 I/II A multicenter phase I/II study of the prophylactic Michael Mauro, MD inhibition of BCR-ABL tyrosine kinase by 503-494-1551 (FHCRC) Tasigna (Nilotinib) after HSCT for Ph+ leukemia Allison Moore RN 503-418-5341 Interstitial pneumonia ASCT0521 II Soluble tumor necrosis factor: Enbrel Bill Chang, MD Syndrome following (Etanercept) for the treatment of acute non- 503-494-0829 Allogeneic stem cell (COG) infectious pulmonary dysfunction (interstitial transplant pneumonia syndrome) following allogeneic stem Allison Moore RN cell transplantation. 503-418-5341